Highest risk: Visual Distraction · FDA letter on file
Highest risk: Visual Distraction
Highest risk: Efficacy
New FDA enforcement letter incorporated (Sep 9, 2025: Attruby). 5 violation patterns detected.
You're receiving this because you're subscribed to Video Content Compliance Monitor alerts. Manage preferences